Cetuximab plus FOLFIRINOX (ERBIRINOX) as first-line treatment for unresectable metastatic colorectal cancer: a phase II trial
about
Effectiveness and safety of monoclonal antibodies for metastatic colorectal cancer treatment: systematic review and meta-analysisHow to select the optimal treatment for first line metastatic colorectal cancerBacterial immunotherapy of gastrointestinal tumors.Treatment with bevacizumab and FOLFOXIRI in patients with advanced colorectal cancer: presentation of two novel trials (CHARTA and PERIMAX) and review of the literature.Dose escalating study of cetuximab and 5-FU/folinic acid (FA)/oxaliplatin/irinotecan (FOLFOXIRI) in first line therapy of patients with metastatic colorectal cancerUpfront FOLFOXIRI+bevacizumab followed by fluoropyrimidin and bevacizumab maintenance in patients with molecularly unselected metastatic colorectal cancer.Detection of low-abundance KRAS mutations in colorectal cancer using microfluidic capillary electrophoresis-based restriction fragment length polymorphism method with optimized assay conditionsDual targeting of HER1/EGFR and HER2 with cetuximab and trastuzumab in patients with metastatic pancreatic cancer after gemcitabine failure: results of the "THERAPY"phase 1-2 trialComet assay measures of DNA damage as biomarkers of irinotecan response in colorectal cancer in vitro and in vivoPancreatic Cancer: Progress in Systemic Therapy.A triplet combination with irinotecan (CPT-11), oxaliplatin (LOHP), continuous infusion 5-fluorouracil and leucovorin (FOLFOXIRI) plus cetuximab as first-line treatment in KRAS wt, metastatic colorectal cancer: a pilot phase II trialA multi-center phase Ib study of oxaliplatin (NSC#266046) in combination with fluorouracil and leucovorin in pediatric patients with advanced solid tumors.Understanding the FOLFOXIRI-regimen to optimize treatment for metastatic colorectal cancerLean body mass as an independent determinant of dose-limiting toxicity and neuropathy in patients with colon cancer treated with FOLFOX regimens.What is the optimal neo-adjuvant treatment for liver metastasis?Sequencing of treatment in metastatic colorectal cancer: where to fit the targetRole of cetuximab in first-line treatment of metastatic colorectal cancerMicroRNA-203 predicts human survival after resection of colorectal liver metastasis.Association between KRAS codon 13 mutations and clinical response to anti-EGFR treatment in patients with metastatic colorectal cancer: results from a meta-analysis.Impact of cetuximab in current treatment of metastatic colorectal cancer.First-line chemotherapy for mCRC—a review and evidence-based algorithm.A Review of Clinical Studies and Practical Guide for the Administration of Triplet Chemotherapy Regimens with Bevacizumab in First-line Metastatic Colorectal CancerA randomized phase II trial of three intensified chemotherapy regimens in first-line treatment of colorectal cancer patients with initially unresectable or not optimally resectable liver metastases. The METHEP trial.Systemic treatment of liver metastases from colorectal cancer.Conversion to resection of liver metastases from colorectal cancer with hepatic artery infusion of combined chemotherapy and systemic cetuximab in multicenter trial OPTILIV.Phosphatase and tensin homolog expression related to cetuximab effects in colorectal cancer patients: a meta-analysis.FOLFOXIRI in combination with panitumumab as first-line treatment in quadruple wild-type (KRAS, NRAS, HRAS, BRAF) metastatic colorectal cancer patients: a phase II trial by the Gruppo Oncologico Nord Ovest (GONO).A triplet combination with capecitabine/oxaliplatin/irinotecan (XELOXIRI) plus cetuximab as first-line therapy for patients with metastatic colorectal cancer: a dose escalation study.Phase I study of primary treatment with 5-FU, oxaliplatin, irinotecan, levofolinate, and panitumumab combination chemotherapy in patients with advanced/recurrent colorectal cancer involving the wild-type RAS gene: the JACCRO CC-14 study.Activity and Safety of Cetuximab Plus Modified FOLFOXIRI Followed by Maintenance With Cetuximab or Bevacizumab for RAS and BRAF Wild-type Metastatic Colorectal Cancer: A Randomized Phase 2 Clinical Trial.Pharmacokinetics of Irinotecan, Oxaliplatin and 5-Fluorouracil During Hepatic Artery Chronomodulated Infusion: A Translational European OPTILIV Study.TRIPLETE: a randomised phase III study of modified FOLFOXIRI plus panitumumab versus mFOLFOX6 plus panitumumab as initial therapy for patients with unresectable and wild-type metastatic colorectal cancerSynchronous liver metastases in patients with rectal cancer: can we establish which treatment first?
P2860
Q26777704-2653FE3B-D7EC-40EF-B04C-58FC640E2019Q27026516-C8875FAF-2377-4883-ACB9-F3AC7EBA71CCQ34242204-8EECBD8F-2170-45D8-8130-3B0592BAD9E0Q34294365-EE21A2AC-144A-4B3B-85EC-A9590E31AC38Q34468886-F13049AD-FD19-4CD6-88A0-D6F1DEBDE1F2Q34492273-939B5413-E8C9-4491-A363-F625FBDFCFB9Q34565052-413F0089-65DF-46A7-BD50-48F547C914E3Q35828693-139D7371-F5CA-47CC-BDA0-962A2DEDAEC9Q36051757-E3135D52-2285-476F-9501-E992B97042B1Q36344551-4E5CBC61-3621-4A06-B0D7-D7F3A97AB5AAQ36451765-CC110DA9-3CE9-4679-A9EF-8A1F80D2ABCEQ36467960-AEF3E296-FC91-45C3-A978-E8D08B1495D3Q36706109-D5F011B4-24A4-4E05-8F5A-7A1ABEC6C7E8Q36797250-08404393-3011-4472-A87D-284037262321Q36999699-42583455-2A72-4066-8328-103FF8FA95BFQ37602729-48FE062C-68B0-47EB-8AE8-DC356DC8B12DQ37708010-5FEDDEB1-56AF-4973-AC65-C9E6C28629D2Q37745844-876700BB-AE57-4798-A941-C733C779697DQ38054578-FD59AE88-D95F-442D-BBDB-AAF37F85DE4FQ38183447-B07BE7F4-F219-4761-ADBC-C5A3B5B9209EQ38555200-E343A47F-F2B0-4493-9B56-E4E5CB95E6F9Q38674714-B5D1330B-5538-4631-9F69-2D1BB2FD7AA6Q39365352-34DE8906-26FF-49F3-A7A8-17F8D737578EQ39949794-B6561019-87CF-40C8-BF09-36657BA521EFQ41116981-C81F7DAC-9CFA-4ADC-94FD-22C16DB43D04Q42187007-EA63947E-D1A8-4FBA-BEEB-2CFB8D433A67Q43649036-54117DA0-4C80-4A5B-93D3-DEA38537E701Q47642789-BAD70C56-BF46-44AA-9321-536DCEA9D117Q49722703-0EA4F8DE-BB2B-453B-AD2B-D8C6FD3095E5Q49951874-520423BB-232F-4FA3-B44F-D71E79DAA41FQ53064537-192C6D12-7E23-4CAA-A05A-DFECB392B420Q56368555-CF301E61-E75A-4C37-A48C-F64FD11039B8Q58797711-00E9D19E-7126-4DD0-A7AB-E237D95B0F3D
P2860
Cetuximab plus FOLFIRINOX (ERBIRINOX) as first-line treatment for unresectable metastatic colorectal cancer: a phase II trial
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Cetuximab plus FOLFIRINOX (ERB ...... ectal cancer: a phase II trial
@ast
Cetuximab plus FOLFIRINOX (ERB ...... ectal cancer: a phase II trial
@en
type
label
Cetuximab plus FOLFIRINOX (ERB ...... ectal cancer: a phase II trial
@ast
Cetuximab plus FOLFIRINOX (ERB ...... ectal cancer: a phase II trial
@en
prefLabel
Cetuximab plus FOLFIRINOX (ERB ...... ectal cancer: a phase II trial
@ast
Cetuximab plus FOLFIRINOX (ERB ...... ectal cancer: a phase II trial
@en
P2093
P2860
P921
P1433
P1476
Cetuximab plus FOLFIRINOX (ERB ...... ectal cancer: a phase II trial
@en
P2093
Andrew Kramar
Emmanuelle Samalin
Eric Assenat
Evelyne Crapez-Lopez
Fabienne Portales
Francoise Desseigne
Frédéric Bibeau
Frédéric Viret
Jean Pierre Bleuse
Laurent Mineur
P2860
P304
P356
10.1634/THEONCOLOGIST.2011-0141
P577
2011-10-20T00:00:00Z